Evidence map›Paper›PMID 35096253›Full record

ArticleThe Journal of clinical and aesthetic dermatology2021

Risk Factors and Predictors of Survival Among Patients with Amelanotic Melanoma Compared to Melanotic Melanoma in the National Cancer Database.

Zachary H Hopkins, Ryan P Carlisle, Zachary E Frost, Julia A Curtis, Laura K Ferris, Aaron M Secrest

Open access · greenAbstract read
In one paragraph

Article in The Journal of clinical and aesthetic dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Amelanotic Melanoma-Biochemical and Molecular Induction Pathways.International journal of molecular sciences · 2024
    Review
  6. Article
  7. Article
  8. Amelanotic Melanoma Treated as Fungal Infection for Years.Case reports in dermatological medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Zachary H HopkinsDrs. Hopkins, Curtis, and Secrest are with the Department of Dermatology, University of Utah in Salt Lake City, Utah.
Ryan P CarlisleDrs. Hopkins, Curtis, and Secrest are with the Department of Dermatology, University of Utah in Salt Lake City, Utah.
Zachary E FrostDrs. Hopkins, Curtis, and Secrest are with the Department of Dermatology, University of Utah in Salt Lake City, Utah.
Julia A CurtisDrs. Hopkins, Curtis, and Secrest are with the Department of Dermatology, University of Utah in Salt Lake City, Utah.
Laura K FerrisDrs. Hopkins, Curtis, and Secrest are with the Department of Dermatology, University of Utah in Salt Lake City, Utah.
Aaron M SecrestDrs. Hopkins, Curtis, and Secrest are with the Department of Dermatology, University of Utah in Salt Lake City, Utah.
University of Pittsburgh · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAmelanotic melanoma (AM) is a rare form of melanoma lacking pigment. Data on AM risk factors and factors predicting survival are limited.

objectivesWe sought to identify predictors of AM, survival differences in AM and melanotic melanoma, and AM-specific survival rates.

methodsUsing 2004 through 2015 National Cancer Database data, we compared 358,543 melanoma cases to 1,384 AM cases. Multivariable logistic regression identified AM risk factors, and AM survival was explored using Kaplan-Meier and multivariable Cox regression.

resultsIncreased age; tumor location on the face, scalp, and neck; increased Breslow thickness; metastatic disease; ulceration; and higher mitotic rate were associated with AM. Five- and ten-year survival rates were higher for patients with MM (melanotic melanoma) than AM tumors (75.4% vs. 58.8% and 62.4% vs 45.1%; log-rank

conclusionAM is more common in older patients on sun-exposed skin and is diagnosed at later stages. Advanced staging at diagnosis explains the survival differences. In patients with AM, regional and metastatic disease were the primary contributors of poorer outcomes. In at-risk patients, the threshold to biopsy should be lower for suspicious nonpigmented lesions.

Indexed as

Amelanotic melanomadermatologymelanomamelanoma survivalNCDBskin cancer

Identifiers

PMID35096253
PMCPMC8794496
OpenAlexW4210821439

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.